Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Korosho Asks METI to Exclude Drug Production Facilities from Planned Electricity Outages
April 11, 2011
- NICE Recommends Aricept for Mild AD
April 11, 2011
- Seikagaku Withdraws PMA for Additional Indication of Supartz in the US
April 11, 2011
- Earthquake Disrupts Production of Some Raw Materials
April 11, 2011
- PMAT, OPMA Petition MREAC on Pass/Fail Criteria for MR Exam
April 11, 2011
- Korosho Requires Revision of Package Insert for Hib Vaccine, Pneumococcal Vaccines
April 11, 2011
- Production, Shipment of Sublood to Resume in Mid-April: Fuso
April 11, 2011
- RAD-AR Completes Patient Database on Antihyperlipidemics
April 11, 2011
- Gov't-Private Sector Dialogue Postponed due to Earthquake
April 11, 2011
- MTPC Aims to Resume Operations at 2 Plants in Mid-April
April 11, 2011
- ProStrakan Shareholders Accept Acquisition by Kyowa Kirin
April 11, 2011
- Shionogi Signs Agreement with Denmark on Industry-Academic Collaboration
April 11, 2011
- Some Companies Postpone April Personnel Changes due to Earthquake
April 11, 2011
- Abbott Japan Completes Acquisition of Former Solvay Pharm.
April 11, 2011
- OncoTherapy Starts PII Trial of Angiogenesis Inhibitor
April 11, 2011
- Eisai Licenses Bexarotene to Minophagen
April 11, 2011
- P&G, Teva to Combine Their OTC Businesses
April 11, 2011
- OncoTherapy Begins Recruitment for Cancer Vaccine Trial
April 11, 2011
- Eisai Enters Collaborative R&D Agreement with PRISM BioLab
April 11, 2011
- BI Japan Starts Operations
April 11, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…